Clinical Trial

Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

Study acronym: ATTEMPT
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 21, 2023 (before its estimated May 2024 completion). Its status may not reflect the trial's current state.
Summary
The ATTEMPT (Adolescent Type 1 diabetes Treatment with SGLT2i for hyperglycEMia \& hyPerfilTration Trial) is a multi-center, double-blinded, randomized, placebo-controlled trial to evaluate the effect of treatment with Dapagliflozin when compared to placebo, in combination with adjustable insulin, on measured GFR in adolescents with T1D 12 to \<19 years of age over a 16-week treatment period.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-04-01; most recent amendment 2026-04-21.
Status change: Active, Not Recruiting → Completed 2026-04-21
Status change: Recruiting → Active, Not Recruiting 2023-11-20
Status change: Not Yet Recruiting → Recruiting 2021-01-05
Trial Details
NCT Number NCT04333823
Lead Sponsor The Hospital for Sick Children
Collaborators: Canadian Institutes of Health Research (CIHR), Juvenile Diabetes Research Foundation
Conditions Diabetes Mellitus, Type 1
Enrollment 100 participants
Start Date 2020-12-11
Primary Completion 2024-05 (estimated)
Study Completion 2024-05 (estimated)
Updated on ClinicalTrials.gov 2023-11-21